REG - Destiny Pharma PLC - Exercise of Options and Total Voting Rights

Destiny PharmaAnnouncement

07/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230707:nRSG2616Fa&default-theme=true

RNS Number : 2616F  Destiny Pharma PLC  07 July 2023

Destiny Pharma plc

("Destiny Pharma" or "the Company")

 

Exercise of Options and Total Voting Rights

 

Brighton, United Kingdom - 07 July 2023 - Destiny Pharma (AIM: DEST), a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life threatening infections, announces that
it has issued and allotted 7,946 new ordinary shares of 1 pence each in the
capital of the Company (the "New Ordinary Shares") following an exercise of
share options by an employee.

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM, with dealings expected to commence on
12 July 2023 ("Admission").

Following Admission, the Company will have a total of 95,271,863 Ordinary
Shares in issue. Shareholders may use this figure of 95,271,863 Ordinary
Shares as the denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their interest
in, the share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

For further information, please contact:

Destiny Pharma plc
Debra Barker, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com
(https://otp.tools.investis.com/clients/uk/destiny_pharma_ltd/rns/about%3Ablank)

Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
(https://otp.tools.investis.com/clients/uk/destiny_pharma_ltd/rns/about%3Ablank)

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2 clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRUNSNROOUBRAR